# Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

> **NCT00670306** · PHASE3 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 528 (actual)

## Conditions studied

- Benign Prostatic Hypertrophy

## Interventions

- **DRUG:** Cetrorelix Pamoate

## Key facts

- **NCT ID:** NCT00670306
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2011-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670306, "Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00670306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*